目的:应用颞侧球结膜眼红指数(TCHI)、眼部症状评分(OSS)及视觉模拟量表(VAS)研究翼状胬肉切除联合自体结膜移植术后患者眼表炎症反应变化情况,并将上述指标应用于抗炎治疗效果评价中,判断其应用有效性。方法:以100例翼状胬肉患者为研...目的:应用颞侧球结膜眼红指数(TCHI)、眼部症状评分(OSS)及视觉模拟量表(VAS)研究翼状胬肉切除联合自体结膜移植术后患者眼表炎症反应变化情况,并将上述指标应用于抗炎治疗效果评价中,判断其应用有效性。方法:以100例翼状胬肉患者为研究对象,均采取翼状胬肉切除联合自体结膜移植术治疗,术后对眼表炎症进行治疗。评估术前,术后1、3、7、10 d,术后1、2个月眼表炎症,应用眼表综合分析仪对TCHI做出评估,观察OSS、VAS评分等主观量化指标的动态变化,采用荧光素钠染色法对角膜上皮愈合情况进行观察,并测量最佳矫正视力(BCVA)。结果:患者术后2个月BCVA明显较术前低(P<0.05)。术后10 d患者角膜无荧光素染色出现,提示角膜上皮缺损愈合完全。术后1 d OSS评分及TCHI值高于术前(均P<0.05);随着抗炎治疗的开展,患者术后7 d OSS评分及TCHI值均降至术前水平(均P>0.05);患者术后1、2个月上述指标均较术前低(均P<0.05)。患者术后1 d VAS评分高于术前(P<0.05);随着抗炎治疗的开展,患者术后7 d VAS评分降至术前水平(P>0.05);术后2个月VAS评分较术前低(P<0.05)。结论:OSS、VAS评分及TCHI可对行翼状胬肉切除联合自体结膜移植术治疗患者的炎症状态做出有效评估,并可作为抗炎治疗有效性的评价指标。展开更多
AIM: To find the risk factors related to the reproliferation of the pterygial tissue after excision and graft surgery.METHODS: Charts of 130 eyes of 130 patients who had pterygial excision from March 2006 to April 201...AIM: To find the risk factors related to the reproliferation of the pterygial tissue after excision and graft surgery.METHODS: Charts of 130 eyes of 130 patients who had pterygial excision from March 2006 to April 2011 were reviewed. Preoperative pterygium morphology, surgical methods, and adjunctive treatments were statistically analyzed for their relationship with recurrence.RESULTS: During the follow-up period, recurrence was observed in 20 eyes(15.4%). None of the preoperative morphologic features were affected the rate of the recurrence. However, an age 【40y [P =0.085, odds ratio(OR) 3.609, 95% confidence interval(CI) 0.838-15.540]and amniotic membrane graft instead of conjunctival autograft(P =0.002, OR 9.093, 95% CI 2.316-35.698) were statistically significant risk factors for recurrence.Multivariate analysis revealed that intraoperative mitomycin C(MMC)(P =0.072, OR 0.298, 95% CI 0.080-1.115)decreased the rate of recurrence. CONCLUSION: Younger age is a risk factor for reproliferation of pterygial tissue after excision and amniotic membrane transplantation(AMT) are less effective in preventing recurrence of pterygium after excision based on the comparison between conjunctival autograft and AMT. Intraoperative MMC application and conjunctival autograft reduce recurrence.展开更多
Purpose:To compare the efficacy of pterygium resection combined with conjunctival autograft versus pterygium resection combined with amniotic membrane transplantation in the treatment of pterygium. Methods: A total of...Purpose:To compare the efficacy of pterygium resection combined with conjunctival autograft versus pterygium resection combined with amniotic membrane transplantation in the treatment of pterygium. Methods: A total of 118 cases (133 eyes) were randomly assigned to receive pterygium resection combined with conjunctival autograft (n=81) or pterygium resection combined with amniotic membrane transplantation(n=52)..Corneal wound healing and neovascularization and the presence or absence of conjunctival proliferation and hyperemia were analyzed at 12 months post-operatively. Results: In the conjunctival autograft group, 6 eyes (7.4%) had recurrent pterygium,.while in the amniotic membrane transplantation group, 10 eyes showed recurrence (19.2%,P<0.05,.chi-square)..Patients in the conjunctival autograft group recovered significantly faster compared with those in the amniotic membrane transplantation group. Conclusion:.Patients receiving pterygium surgery combined with conjunctival autograft had lower recurrence rates and experience faster recovery compared with those undergoing pterygium resection combined with amniotic membrane transplantation.展开更多
Limbal stem cell deficiency(LSCD)causes severe vision impairment and can lead to blindness,representing one of the most challenging ocular surface disorders.Stem cell deficiency can be congenital or,more often,acquire...Limbal stem cell deficiency(LSCD)causes severe vision impairment and can lead to blindness,representing one of the most challenging ocular surface disorders.Stem cell deficiency can be congenital or,more often,acquired.The categorization of ocular surface transplantation techniques is crucial to achieving treatment homogeneity and quality of care,according to the anatomic source of the tissue being transplanted,genetic source,autologous or allogenic transplantation(to reflect histocompatibility in the latter group),and cell culture and tissue engineering techniques.The aim of this minireview is to provide a summary of the management of LSCD,from clinical characteristics and therapeutic outcomes to the development of novel therapeutic approaches.The manuscript also briefly summarizes recent findings in the current literature and outlines the future challenges to overcome in the management of the major types of ocular surface failure.展开更多
文摘目的:应用颞侧球结膜眼红指数(TCHI)、眼部症状评分(OSS)及视觉模拟量表(VAS)研究翼状胬肉切除联合自体结膜移植术后患者眼表炎症反应变化情况,并将上述指标应用于抗炎治疗效果评价中,判断其应用有效性。方法:以100例翼状胬肉患者为研究对象,均采取翼状胬肉切除联合自体结膜移植术治疗,术后对眼表炎症进行治疗。评估术前,术后1、3、7、10 d,术后1、2个月眼表炎症,应用眼表综合分析仪对TCHI做出评估,观察OSS、VAS评分等主观量化指标的动态变化,采用荧光素钠染色法对角膜上皮愈合情况进行观察,并测量最佳矫正视力(BCVA)。结果:患者术后2个月BCVA明显较术前低(P<0.05)。术后10 d患者角膜无荧光素染色出现,提示角膜上皮缺损愈合完全。术后1 d OSS评分及TCHI值高于术前(均P<0.05);随着抗炎治疗的开展,患者术后7 d OSS评分及TCHI值均降至术前水平(均P>0.05);患者术后1、2个月上述指标均较术前低(均P<0.05)。患者术后1 d VAS评分高于术前(P<0.05);随着抗炎治疗的开展,患者术后7 d VAS评分降至术前水平(P>0.05);术后2个月VAS评分较术前低(P<0.05)。结论:OSS、VAS评分及TCHI可对行翼状胬肉切除联合自体结膜移植术治疗患者的炎症状态做出有效评估,并可作为抗炎治疗有效性的评价指标。
基金Supported by Biomedical Research Institute grant, Kyungpook National University Hospital at 2013
文摘AIM: To find the risk factors related to the reproliferation of the pterygial tissue after excision and graft surgery.METHODS: Charts of 130 eyes of 130 patients who had pterygial excision from March 2006 to April 2011 were reviewed. Preoperative pterygium morphology, surgical methods, and adjunctive treatments were statistically analyzed for their relationship with recurrence.RESULTS: During the follow-up period, recurrence was observed in 20 eyes(15.4%). None of the preoperative morphologic features were affected the rate of the recurrence. However, an age 【40y [P =0.085, odds ratio(OR) 3.609, 95% confidence interval(CI) 0.838-15.540]and amniotic membrane graft instead of conjunctival autograft(P =0.002, OR 9.093, 95% CI 2.316-35.698) were statistically significant risk factors for recurrence.Multivariate analysis revealed that intraoperative mitomycin C(MMC)(P =0.072, OR 0.298, 95% CI 0.080-1.115)decreased the rate of recurrence. CONCLUSION: Younger age is a risk factor for reproliferation of pterygial tissue after excision and amniotic membrane transplantation(AMT) are less effective in preventing recurrence of pterygium after excision based on the comparison between conjunctival autograft and AMT. Intraoperative MMC application and conjunctival autograft reduce recurrence.
文摘Purpose:To compare the efficacy of pterygium resection combined with conjunctival autograft versus pterygium resection combined with amniotic membrane transplantation in the treatment of pterygium. Methods: A total of 118 cases (133 eyes) were randomly assigned to receive pterygium resection combined with conjunctival autograft (n=81) or pterygium resection combined with amniotic membrane transplantation(n=52)..Corneal wound healing and neovascularization and the presence or absence of conjunctival proliferation and hyperemia were analyzed at 12 months post-operatively. Results: In the conjunctival autograft group, 6 eyes (7.4%) had recurrent pterygium,.while in the amniotic membrane transplantation group, 10 eyes showed recurrence (19.2%,P<0.05,.chi-square)..Patients in the conjunctival autograft group recovered significantly faster compared with those in the amniotic membrane transplantation group. Conclusion:.Patients receiving pterygium surgery combined with conjunctival autograft had lower recurrence rates and experience faster recovery compared with those undergoing pterygium resection combined with amniotic membrane transplantation.
文摘Limbal stem cell deficiency(LSCD)causes severe vision impairment and can lead to blindness,representing one of the most challenging ocular surface disorders.Stem cell deficiency can be congenital or,more often,acquired.The categorization of ocular surface transplantation techniques is crucial to achieving treatment homogeneity and quality of care,according to the anatomic source of the tissue being transplanted,genetic source,autologous or allogenic transplantation(to reflect histocompatibility in the latter group),and cell culture and tissue engineering techniques.The aim of this minireview is to provide a summary of the management of LSCD,from clinical characteristics and therapeutic outcomes to the development of novel therapeutic approaches.The manuscript also briefly summarizes recent findings in the current literature and outlines the future challenges to overcome in the management of the major types of ocular surface failure.
